The Effects of Chloroquine and Hydroxychloroquine on ACE2-Related Coronavirus Pathology and the Cardiovascular...

Area of Science:

• Virology
• Pharmacology
• Cardiology

Background:

• The COVID-19 pandemic caused by SARS-CoV-2 presents a global health challenge with no current effective antiviral treatments.
• Chloroquine (CQ) and hydroxychloroquine (HCQ), used for malaria, are being investigated for COVID-19 treatment.
• These drugs may inhibit SARS-CoV-2 entry via ACE2 and subsequent viral processes, but also pose cardiovascular risks.

Purpose of the Study:

• To critically review existing evidence on the potential use of CQ and HCQ for COVID-19 treatment.
• To examine the proposed mechanisms of action, including effects on the cardiovascular system.
• To identify gaps in current research and guide future studies.

Main Methods:

• A comprehensive review of published scientific literature.
• Critical analysis of evidence regarding antiviral effects and cardiovascular impacts of CQ and HCQ.
• Examination of proposed mechanisms of SARS-CoV-2 inhibition and cardiovascular damage.

Main Results:

• CQ and HCQ show potential as inhibitors of SARS-CoV-2 entry and intracellular replication.
• Evidence suggests these drugs may impact the cardiovascular system, with both potential benefits and risks.
• The precise mechanisms underlying both antiviral activity and cardiotoxicity require further elucidation.

Conclusions:

• CQ and HCQ may be beneficial for treating COVID-19 and other ACE2-mediated viral infections.
• More rigorous, well-designed randomized clinical trials are essential to validate antiviral efficacy and cardiovascular safety.
• Understanding their mechanisms of action could enhance knowledge of COVID-19 pathology, even if they prove clinically ineffective.